Focused ultrasound shows promise against deadliest brain tumor

(University of Virginia Health System) Focused sound waves create tiny bubbles inside cancer cells, causing them to die.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

ConclusionOur results suggest that SDT with FL and low-intensity FUS is effective in inhibiting the growth of ectopic malignant gliomas in rats. The selective FL extravasation and accumulation in the tumor areas where the blood –brain barrier is damaged suggests the tumor-specificity of the treatment. The possibility to use this treatment in intracranial models and in human gliomas will have to be explored in further studies.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Multimodality 3D optical/CT and PET are valid translational methods to confirm drug delivery through a permeabilized BBB that can be used to enhance drug development in a preclinical setting. Furthermore, PET scanning using radiolabeled therapeutics has the potential to be translated to humans, as HIFU-mediated BBB permeability has entered early stage clinical trials. Support: NIH/NCI 5P01CA207206. The PET early drug development program is supported by the Columbia Dept. of Radiology and Irving Institute CTSA Translational Therapeutics Accelerator (UL1TR001873).
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Novel Nonradioactive Probes (Poster Session) Source Type: research
Abstract Pediatric brain tumors are the most common solid tumor and the first cause of cancer death in childhood, adolescence, and young adulthood. Current treatments are far from optimal in most of these tumors and the prognosis remains dismal for many of them. One of the main causes of the failure of current medical treatments is in part due to the existence of the blood-brain barrier (BBB), which limits drug delivery to tumors. Opening of the BBB with low-intensity pulsed ultrasound (LIPU) has emerged during the last 2 decades as a promising technique for enhancing drug delivery to the brain. In preclinical mod...
Source: Neurosurgical Focus - Category: Neurosurgery Authors: Tags: Neurosurg Focus Source Type: research
Northwestern Medicine scientists are using an implantable ultrasound technology to help deliver treatment for glioblastoma to the brain. The researchers detailed how they used the ultrasound to open the blood-brain barrier in mice in Clinical Cancer Research, a journal of the American Association for Cancer Research. The scientists also discovered brain toxicity for the conventional formulation for this drug - paclitaxel -to the brain was caused by the solution required to dissolve the drug (cremophor.) Scientists tested a new formulation of the drug that uses albumin as opposed to cremophor, and it was not har...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
(Northwestern University) A potent drug for glioblastoma can't be used in patients. It can't reach its target because it's blocked by the blood-brain barrier, and the conventional formulation for this drug is toxic to the brain. But now scientists have used a novel technology for opening the blood-brain barrier with an implantable ultrasound, and delivered the powerful drug to the tumor in mice. Scientists also identified why drug is toxic and tested a new formulation not harmful to the brain.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: Ultrasound delivery of paclitaxel across the BBB is a feasible and effective treatment for glioma. ABX is the preferred formulation for further investigation in the clinical setting due to its superior brain penetration and tolerability compared with CrEL-PTX. PMID: 31831565 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Shah Islam Hugh Harvey By HUGH HARVEY, MBBS and SHAH ISLAM, MBBS AI in medical imaging entered the consciousness of radiologists just a few years ago, notably peaking in 2016 when Geoffrey Hinton declared radiologists’ time was up, swiftly followed by the first AI startups booking exhibiting booths at RSNA. Three years on, the sheer number and scale of AI-focussed offerings has gathered significant pace, so much so that this year a decision was made by the RSNA organising committee to move the ever-growing AI showcase to a new space located in the lower level of the North Hall. In some ways it made sense to ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Artificial Intelligence Health Tech Start-Ups AI Hugh Harvey Radiology RSNA RSNA 2019 RSNA19 Shah Islam Source Type: blogs
Gliomas comprise approximately 30% of all primary brain tumors (BTs). Glioblastoma multiforme (GBM) accounts for more than half of all gliomas and is a highly malignant form of brain cancer with a 5-year survival rate of
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Review Article Source Type: research
Abstract High-grade gliomas (HGGs) are aggressive primary brain tumors that confer poor prognoses. Despite aggressive combined modality treatment, HGGs invariably recur. Considerable research efforts and resources have focused on identification of novel therapies for HGGs; however, standard treatments have not changed significantly in more than 10 years, since the introduction of concurrent chemoradiation therapy with temozolomide. Hyperthermia (HT) has been shown to enhance the efficacy of radiation treatment (RT) in numerous cancer types through multiple mechanisms, including impairment of DNA repair pathways,...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
In this study, we evaluated whether the combination of focused ultrasound (FUS) and microbubbles can improve adoptively NK-92MI cell infiltration into ovarian tumors through biodistribution, immunofluorescence, and flow cytometry. The treatment effects of using this strategy twice a week were explored. The potential molecular mechanism of FUS assisting NK cell therapy was also initially explored through evaluating the expression of ICAM1 and CX3CL1 by qRT-PCR. Our results indicated that FUS and microbubbles can improve NK-92MI cells’ infiltration into tumors, and the combination of FUS and NK-92MI cells had a better ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | International Medicine & Public Health | Neurology | Ultrasound